In addition to its effects on weight and energy, there is emerging evidence that L-carnitine may have positive impacts on reproductive health
SUSTAIN-6 showed that semaglutide reduced major adverse cardiovascular events by 26%
Triple receptor activity: GLP-1, GIP, and glucagon Appetite and satiety pathway support Energy expenditure and fat metabolism research Body weight reduction in clinical trials Potential metabolic health improvements A possible future option for clients who have plateaued on existing therapies In a phase 2 trial published in The New England Journal of Medicine, adults with obesity who received Retatrutide for 48 weeks had substantial reductions in body weight, with the 12 mg group showing a mean percentage change of -24.2% compared with -2.1% for placebo
GLP-1 receptor agonists are typically prescribed for individuals who are struggling with obesity or overweight, particularly when traditional weight loss methods have proven insufficient
One of the novel technologies, diffusion tensor imaging (DTI), offers new tools for evaluating peripheral nerve integrity and monitoring the effects of treatment in DPN
Pricing for semaglutide protocols starts at 5,660 per month and varies with brand and dose